Disease Markers / 2019 / Article / Tab 4

Research Article

sFlt-1/PlGF Ratio as a Predictive Marker in Women with Suspected Preeclampsia: An Economic Evaluation from a Swiss Perspective

Table 4

Comparison of costs for the no-test and test (sFlt-1/PlGF) strategies and difference in total and per patient costs.

ServiceNo-test strategyTest strategyDifference (€)
Cost (€)Cost (€)

Initial consultation60843,228,22060843,228,220
Outpatient care
 Low165513,068,335218517,248,215+4,179,880
 Intermediate165517,452,138249826,666,335+9,214,197
 Intermediate (after hospitalization)161322,116,2445808,611,745–13,504,499
Hospitalization
 Suspected preeclampsia with birth5834,906,0133803,191,864–1,714,150
 Preeclampsia after ambulatory care5775,698,4124424,560,054–1,138,357
Total medical costs608466,469,362608463,506,433–2,962,929
sFlt-1/PlGF evaluation06084856,627+856,627
Overall costs
 Total608466,469,362608464,363,060–2,106,301
 Per patient608410,925608410,579–346

PlGF: placental growth factor; sFlt-1: soluble fms-like tyrosine kinase-1.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.